Table 2 Primary endpoint of GvHD outcomes after receiving SARS-CoV2 vaccination
|  | Overall (N = 298) | 1st Dose (N = 298) | 2nd Dose (N = 298) | Booster (N = 54) |
|---|---|---|---|---|
New GvHD, n (%) | 26 (8.7) | 6 (2.0) | 18 (6.0) | 2 (3.7) |
Median time to GvHD, days (range) | – | 20 days (3–28) | 25 days (2–41) | 9.5 days (6–13) |
GvHD Severity, n (%) | ||||
 Mild | 11 (42.3) | 2 (33.3) | 8 (44.4) | 1 (50.0) |
 Moderate | 9 (34.6) | 3 (50.0) | 6 (33.3) | 0 (0) |
 Severe | 6 (23.1) | 1 (16.7) | 4 (22.2) | 1 (50.0) |
Location | ||||
 Skin/Joints | 12 (46.2) | 3 (50.0) | 8 (44.4) | 1 (50.0) |
 Mouth | 9 (34.6) | 1 (16.7) | 7 (38.9) | 1 (50.0) |
 GI | 2 (7.7) | 0 (0) | 2 (11.1) | 0 (0) |
 Liver | 6 (23.1) | 2 (33.3) | 3 (16.7) | 1 (50.0) |
 Eyes | 4 (15.4) | 0 (0) | 4 (22.2) | 0 (0) |
 Other | 5 (19.2) | 1 (16.7) | 4 (22.2) | 0 (0) |
Worsen GvHD, n (%) | 16 (5.3) | 8 (2.7) | 8 (2.7) | 0 (0) |
Median time to GvHD, days (range) |  | 21.5 days (6–28) | 31.5 days (4–39) | NA |
GvHD Severity, n (%) | ||||
 Mild | 3 (18.7) | 0 (0) | 3 (37.5) | NA |
 Moderate | 5 (31.3) | 3 (38.0) | 2 (25.0) |  |
 Severe | 8 (50.0) | 5 (62.0) | 3 (37.5) |  |
Location | ||||
 Skin/Joints | 12 (75.0) | 7 (87.5) | 5 (62.5) | NA |
 Mouth | 5 (31.3) | 1 (12.5) | 4 (50.0) |  |
 GI | 3 (18.7) | 2 (25.0) | 1 (12.5) |  |
 Liver | 0 (0) | 0 (0) | 0 (0) |  |
 Eyes | 3 (18.7) | 1 (12.5) | 2 (25.0) |  |
 Other | 0 (0) | 0 (0) | 0 (0) |  |